Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice

被引:49
|
作者
Sun, Lei [1 ]
Yang, Xiaoxiao [2 ]
Li, Qi [1 ]
Zeng, Peng [1 ]
Liu, Ying [1 ]
Liu, Lipei [1 ]
Chen, Yuanli [2 ]
Yu, Miao [1 ]
Ma, Chuanrui [1 ]
Li, Xiaoju [1 ]
Li, Yan [1 ]
Zhang, Rongxin [3 ]
Zhu, Yan [4 ]
Miao, Qing Robert [5 ,6 ]
Han, Jihong [2 ,7 ]
Duan, Yajun [2 ,7 ]
机构
[1] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, Tianjin, Peoples R China
[2] Hefei Univ Technol, Coll Biomed Engn, Dept Biomed Sci, Hefei, Peoples R China
[3] Tianjin Med Univ, Dept Physiol, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Pharmacol, Tianjin, Peoples R China
[5] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA
[6] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[7] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China
基金
中国国家自然科学基金; 对外科技合作项目(国际科技项目);
关键词
adiponectin; adiponectin receptors; AMP-activated protein kinases; atherosclerosis; peroxisome proliferator-activated receptors; PLASMA-PROTEIN; PPAR-GAMMA; PCSK9; CHOLESTEROL; TRANSCRIPTION; MODULATOR; LIGANDS; AGONIST; STATINS; BINDING;
D O I
10.1161/ATVBAHA.117.309630
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPAR gamma (peroxisome proliferator-activated receptor.) or SREBP2 (sterol regulatory element-binding protein 2). The effects of AdipoR agonists on PCSK9 and LDLR expression, serum lipid profiles, and atherosclerosis remain unknown. Approach and Results-At cellular levels, AdipoR agonists (ADP355 and AdipoRon) induced PCSK9 transcription/expression that solely depended on activation of PPAR-responsive element in the PCSK9 promoter. AdipoR agonists induced PPAR gamma expression; thus, the AdipoR agonist-activated PCSK9 expression/production was impaired in PPAR gamma deficient hepatocytes. Meanwhile, AdipoR agonists transcriptionally activated LDLR expression by activating SRE in the LDLR promoter. Moreover, AMP-activated protein kinase alpha (AMPK alpha) was involved in AdipoR agonist-activated PCSK9 expression. In wild-type mice, ADP355 increased PCSK9 and LDLR expression and serum PCSK9 levels, which was associated with activation of PPAR gamma, AMPK alpha and SREBP2 and reduction of LDL-cholesterol levels. In contrast, ADP355 reduced PCSK9 expression/secretion in apoE-deficient (apoE(-/-)) mice, but it still activated hepatic LDLR, PPAR gamma, AMPK alpha, and SREBP2. More importantly, ADP355 inhibited lesions in en face aortas and sinus lesions in aortic root in apoE(-/-) mice with amelioration of lipid profiles. Conclusions-Our study demonstrates that AdipoR activation by agonists regulated PCSK9 expression differently in wildtype and apoE(-/-) mice. However, ADP355 activated hepatic LDLR expression and ameliorated lipid metabolism in both types of mice and inhibited atherosclerosis in apoE(-/-) mice. Visual Overview-An online visual overview is available for this article.
引用
收藏
页码:1290 / +
页数:22
相关论文
共 50 条
  • [1] ACTIVATION OF ADIPONECTIN RECEPTOR INDUCES PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 EXPRESSION BUT AMELIORATES LIPID PROFILES IN MICE
    Sun, L.
    Yang, X.
    Chen, Y.
    Duan, Y.
    Han, J.
    CARDIOLOGY, 2017, 137 : 74 - 74
  • [2] Proprotein Convertase Subtilisin/Kexin Type 9
    Lu
    Daugherty
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (04) : E32 - E32
  • [3] Activation of Adiponectin Receptors Induces Proprotein Convertase Subtilisin Kexin Type 9 Expression by Activating PPARgamma Pathway
    Sun, Lei
    Yang, Xiaoxiao
    Liu, Ying
    Chen, Yuanli
    Han, Jihong
    Duan, Yajun
    FASEB JOURNAL, 2016, 30
  • [4] Proprotein Convertase Subtilisin/kexin Type 9 Interacts and Regulates ApolipoproteinB
    Sun, Hua
    Caskey, C. Thomas
    Teng, Ba-Bie
    CIRCULATION, 2010, 122 (21)
  • [5] Mice Deficient for Proprotein Convertase Subtilisin Kexin Type 9 are Protected Against Postprandial Lipemia
    le May, Cedric
    Kourimate, Sanae
    Langhi, Cedric
    Chetiveaux, Maud
    Jarry, Anne
    Comera, Christine
    Collet, Xavier
    Kuipers, Folkert
    Krempf, Michel
    Cariou, Bertrand
    Costet, Philippe
    CIRCULATION, 2008, 118 (18) : S566 - S566
  • [6] Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys
    Wang, Ya
    Ma, Murong
    Wang, Jian-An
    Daugherty, Alan
    Lu, Hong S.
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (02) : 154 - 155
  • [7] Proprotein convertase subtilisin/kexin type 9 inhibition
    Marais, David A.
    Blom, Dirk J.
    Petrides, Francine
    Goueffic, Yann
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 511 - 517
  • [8] Proprotein Convertase Subtilisin/Kexin Type 9 Regulates Migration of Mononuclear Cells
    Just, Isabel A.
    Meyborg, Heike
    Molnar, Sandra
    Urban, Daniel
    Kintscher, Ulrich
    Fleck, Eckart
    Stawowy, Philipp
    CIRCULATION, 2014, 130
  • [9] Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
    Julius U.
    Tselmin S.
    Schatz U.
    Fischer S.
    Bornstein S.R.
    Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) : 45 - 50
  • [10] Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
    Spolitu, Stefano
    Dai, Wen
    Zadroga, John A.
    Ozcan, Lale
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 186 - 191